USPS Expands Electric Vehicle Fleet as Nationwide Transition Accelerates 
UPS MD-11 Crash Prompts Families to Prepare Wrongful Death Lawsuit 
Netflix’s Bid for Warner Bros Discovery Aims to Cut Streaming Costs and Reshape the Industry 
BOJ Governor Ueda Highlights Uncertainty Over Future Interest Rate Hikes 
U.S. Futures Steady as Rate-Cut Bets Rise on Soft Labor Data 
Firelight Launches as First XRP Staking Platform on Flare, Introduces DeFi Cover Feature 
Asian Currencies Steady as Rupee Hits Record Low Amid Fed Rate Cut Bets 
Australia Moves Forward With Teen Social Media Ban as Platforms Begin Lockouts 
European Stocks Rise as Markets Await Key U.S. Inflation Data 
Spain’s Industrial Output Records Steady Growth in October Amid Revised September Figures 
Asia’s IPO Market Set for Strong Growth as China and India Drive Investor Diversification 
Visa to Move European Headquarters to London’s Canary Wharf 
Tesla Faces 19% Drop in UK Registrations as Competition Intensifies 
Oil Prices Rise as Ukraine Targets Russian Energy Infrastructure 
Wikipedia Pushes for AI Licensing Deals as Jimmy Wales Calls for Fair Compensation 
IMF Deputy Dan Katz Visits China as Key Economic Review Nears 
Samsung Biologics just opened the largest Contract Development and Manufacturing Organization (CDMO) plant in the world, and it is located in Incheon, South Korea. The biotech firm is now hoping that through its new pharmaceutical facility, it will be able to replicate the success of its chip manufacturing business.
Samsung Biologics inaugurated the plant on Tuesday, Oct. 11, and it was attended by the vice chairman of Samsung Electronics, Lee Jae Yong. The facility is now the biopharma firm’s fourth factory.
The company usually has an annual production capacity of 240,000 liters and this will now become 420,000 liters as the new plant starts its partial operation. The construction of the Songdo plant began in 2020, and it is expected to go into full operation next year.
As per Korea Joongang Daily, once it runs in full force, Samsung Biologics is expecting to further increase its production capacity up to 620,000 liters. The company said this amount is equivalent to almost 30% of the global contract manufacturing capacity for biopharma firms.
With this volume, Samsung Biologics defeated Switzerland’s Lonza Group AG and Germany's Boehringer Ingelheim pharmaceutical and biotech companies.
In any case, Samsung invested KRW2 trillion or about $1.4 billion for the construction of its new Songdo plant, and in the future, the company may spend a total of KRW7 trillion on building its fifth, sixth, seventh, and eighth plants in the same region but on another site. Samsung Biologics is expanding its facilities to accommodate more orders from its major global clients, such as Pfizer, GlaxoSmithKline, Moderna, Eli Lilly, and AstraZeneca.
Meanwhile, the Samsung chief met with the senior executives of Samsung Biologics and Samsung Bioepis after the inauguration ceremony for the Songdo factory. They talked about mid and long-term strategies to improve competitiveness as CDMO and a biosimilar manufacturer.
The Korea Times reported that at the meeting, Lee Jae Yong vowed to put in a new investment of KRW7.5 trillion or $5.2 billion to widen the gap from its rivals in the bio business and move ahead to become the leader in the industry. He said that Samsung will release the fund for its biotech unit by 2032.
